Damn!! We did not need this resignation on the cusp of our decision date. The dramatic drop in RETA share price, on the eve of its PDUFA is being associated with the (sudden) departure of Billy Dunn and the appoinment of Teresa Buracchio to replace him.
Dunn has faced criticism concerning "the controversial accelerated approval of Biogen’s Alzheimer’s med Aduhelm". Buracchio has been quoted as reiterating that "it is of vital importance and it is legally required for FDA to ensure that drugs are both effective and safe".
Both of the above may be of no consequence to us, but (for me) they open the tiny window of concern just that little bit wider. (Why did this have to complicate matters now?)
Perhaps, surprising that Dunn has chosen to time his resignation to coincide with the Rare Disease recognition day/week, bearing in mind the FDA's involvement in it.
[Bit cheeky I know, but I would welcome an
@hottod comment on this.]
(20min delay)